Gilead Sciences, Inc. $GILD Stock Sold by Nisa Investment Advisors LLC

Key Points

• Nisa Investment Advisors reduced its Gilead Sciences stake by 11.3% in the third quarter, selling 38,166 shares and retaining 298,739 shares valued at approximately $44.5 million. Institutional investors collectively own 83.67% of the company.
• Gilead insiders have sold 111,000 shares worth about $15.9 million over the past 90 days, while CFO Andrew Dickinson and director Anthony Welters disclosed sales conducted under pre-arranged trading plans.
• Gilead’s shares recently traded near $156.51, close to their 12-month high, and the company reported quarterly revenue of $7.8 billion, ahead of estimates. Analysts maintain a Moderate Buy consensus with an average price target of $159.63, and Gilead pays an annualized $3.28 dividend yielding about 2.1%.

Nisa Investment Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 298,739 shares of the biopharmaceutical company's stock after selling 38,166 shares during the period. Nisa Investment Advisors LLC's holdings in Gilead Sciences were worth $44,527,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Integrated Advisors Network LLC boosted its holdings in shares of Gilead Sciences by 6.2% in the 3rd quarter. Integrated Advisors Network LLC now owns 2,461 shares of the biopharmaceutical company's stock worth $367,000 after purchasing an additional 144 shares during the period. Diversify Advisory Services LLC increased its position in shares of Gilead Sciences by 20.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 16,773 shares of the biopharmaceutical company's stock valued at $2,640,000 after purchasing an additional 2,854 shares during the last quarter. 55 North Private Wealth LLC raised its holdings in Gilead Sciences by 17.8% during the 3rd quarter. 55 North Private Wealth LLC now owns 2,173 shares of the biopharmaceutical company's stock valued at $324,000 after buying an additional 329 shares during the period. Prime Capital Investment Advisors LLC raised its holdings in Gilead Sciences by 8.7% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 16,394 shares of the biopharmaceutical company's stock valued at $2,444,000 after buying an additional 1,309 shares during the period. Finally, Net Worth Advisory Group purchased a new stake in Gilead Sciences during the 3rd quarter valued at $229,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock valued at $15,877,860 in the last ninety days. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Trading Up 2.2%

GILD stock opened at $156.51 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The firm's 50-day moving average is $148.01 and its 200 day moving average is $137.50. The company has a market capitalization of $194.06 billion, a PE ratio of -58.62 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences's payout ratio is presently -122.85%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success strengthens the pipeline. Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data were described as “highly competitive,” supporting management’s strategy to expand into immunology and inflammatory bowel disease. Success in a large market could diversify Gilead beyond its HIV franchise. Gilead’s highly competitive mid-stage ulcerative colitis data validate I&I push
• Positive Sentiment: Bank of America raised its price target and maintained a Buy rating. The target increased from $168 to $172, implying roughly 10% upside from the referenced price and signaling confidence in Gilead’s earnings outlook and pipeline prospects.
• Positive Sentiment: Recent FDA decisions add commercial catalysts. Gilead received approval for the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval for Hepcludex in chronic hepatitis delta. The company will also present 28 HIV and antiviral research findings at IDWeek 2026, potentially providing additional clinical updates. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and quantitative sentiment improved. Gilead was upgraded to Zacks Rank #2 (Buy), reflecting improving expectations for earnings prospects. Separately, 43 ETFs added Gilead shares, indicating some institutional demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Investors are weighing acquisitions against Gilead’s dependable HIV cash flow. Biktarvy and other HIV products continue to support recurring revenue and the dividend, but acquisitions such as Arcellx and Tubulis have increased research and integration costs. Gilead reportedly recorded a substantial trailing loss as it absorbs those investments.
• Negative Sentiment: ETF selling and near-term profitability concerns could limit gains. ETFs were also reported as net sellers of Gilead on October 16, while coverage noted that the ulcerative-colitis trial win initially failed to lift the stock. Investors may remain focused on acquisition-related expenses and the path back to sustainable positive earnings. ETFs Are Net Sellers of Gilead Sciences

Wall Street Analysts Forecast Growth

Several research firms have commented on GILD. Bank of America lifted their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a "buy" rating in a research note on Tuesday. Weiss Ratings upgraded shares of Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, September 14th. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $160.00 to $170.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Zacks Research lowered shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 29th. Finally, Barclays dropped their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $159.63.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.